CLINICAL TRIALS PROFILE FOR CATAPRES-TTS-3

All Clinical Trials for CATAPRES-TTS-3

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University Medical Center	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00262470 ↗	Treatment of Orthostatic Intolerance	Active, not recruiting	National Institutes of Health (NIH)	Phase 1/Phase 2	1997-04-01	This trial is designed to study the effects of various mechanistically unique medications in controlling excessive increases in heart rate with standing and in improving the symptoms of orthostatic intolerance in patients with this disorder.
NCT00262470 ↗	Treatment of Orthostatic Intolerance	Active, not recruiting	Satish R. Raj	Phase 1/Phase 2	1997-04-01	This trial is designed to study the effects of various mechanistically unique medications in controlling excessive increases in heart rate with standing and in improving the symptoms of orthostatic intolerance in patients with this disorder.
NCT00329511 ↗	A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy	Withdrawn	Afshan B. Hameed, M.D.	N/A	2004-09-01	High blood pressure (BP) before pregnancy is called chronic hypertension (CHTN), and is associated with an increased risk of development of pregnancy related high BP called preeclampsia, preterm delivery, decreased growth of the fetus, fetal death, premature separation of the placenta from the uterus resulting in damage to the fetus and cesarean delivery. Longer duration and severity of CHTN in pregnancy leads to worse outcomes for the mother and the fetus. Treatment of mild CHTN in pregnancy does not improve these outcomes, and therefore, medications to lower BP are used for moderate to severe hypertension. To date the literature on the medications used in pregnancy is extremely limited. Methyldopa is used as a first choice medicine for CHTN in pregnancy. It acts on the central nervous system (CNS) by relaxation of the blood vessels leading to a decrease in BP. It does not decrease the blood flow to the uterus, placenta, or the fetus (4). Methyldopa is a weak antihypertensive medicine given three or four times a day and frequently needs changes in the dose or may require an additional medication to control BP. This may lead to a greater chance of non compliance. Another option is Clonidine which is an effective antihypertensive treatment and is available in many forms (oral, parenteral, and transdermal.) It acts on the maternal CNS. Clonidine is not associated with teratogenic or neonatal side effects. Transdermal clonidine (catapres-TTS®) is a preparation of clonidine hydrochloride that can be released and absorbed transdermally over a 7-day period. The study will determine differences in compliance between the two antihypertensive regimens- oral methyldopa and Catapres-TTS, comparisons of patient tolerability, compliance and adequacy of BP control, as well as provide information on an alternate option for BP control.
NCT00329511 ↗	A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy	Withdrawn	University of California, Irvine	N/A	2004-09-01	High blood pressure (BP) before pregnancy is called chronic hypertension (CHTN), and is associated with an increased risk of development of pregnancy related high BP called preeclampsia, preterm delivery, decreased growth of the fetus, fetal death, premature separation of the placenta from the uterus resulting in damage to the fetus and cesarean delivery. Longer duration and severity of CHTN in pregnancy leads to worse outcomes for the mother and the fetus. Treatment of mild CHTN in pregnancy does not improve these outcomes, and therefore, medications to lower BP are used for moderate to severe hypertension. To date the literature on the medications used in pregnancy is extremely limited. Methyldopa is used as a first choice medicine for CHTN in pregnancy. It acts on the central nervous system (CNS) by relaxation of the blood vessels leading to a decrease in BP. It does not decrease the blood flow to the uterus, placenta, or the fetus (4). Methyldopa is a weak antihypertensive medicine given three or four times a day and frequently needs changes in the dose or may require an additional medication to control BP. This may lead to a greater chance of non compliance. Another option is Clonidine which is an effective antihypertensive treatment and is available in many forms (oral, parenteral, and transdermal.) It acts on the maternal CNS. Clonidine is not associated with teratogenic or neonatal side effects. Transdermal clonidine (catapres-TTS®) is a preparation of clonidine hydrochloride that can be released and absorbed transdermally over a 7-day period. The study will determine differences in compliance between the two antihypertensive regimens- oral methyldopa and Catapres-TTS, comparisons of patient tolerability, compliance and adequacy of BP control, as well as provide information on an alternate option for BP control.

Clinical Trial Conditions for CATAPRES-TTS-3

Condition Name

Condition Name for CATAPRES-TTS-3
Intervention	Trials
Hypertension	3
Delirium	2
Fecal Incontinence	2
Tourette Syndrome	1

Condition MeSH

Condition MeSH for CATAPRES-TTS-3
Intervention	Trials
Hypertension	3
Delirium	3
Fecal Incontinence	2
Pain, Postoperative	2

Clinical Trial Locations for CATAPRES-TTS-3

Trials by Country

Trials by Country for CATAPRES-TTS-3
Location	Trials
United States	11
United Kingdom	2
Lithuania	1
Denmark	1
Netherlands	1

Trials by US State

Trials by US State for CATAPRES-TTS-3
Location	Trials
Minnesota	3
California	2
Tennessee	2
Maryland	2
Pennsylvania	1

Clinical Trial Progress for CATAPRES-TTS-3

Clinical Trial Phase

Clinical Trial Phase for CATAPRES-TTS-3
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	3
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for CATAPRES-TTS-3
Clinical Trial Phase	Trials
Completed	7
Recruiting	3
Terminated	3

Clinical Trial Sponsors for CATAPRES-TTS-3

Sponsor Name

Sponsor Name for CATAPRES-TTS-3
Sponsor	Trials
Mayo Clinic	3
National Center for Research Resources (NCRR)	2
Simbec Research	1

Sponsor Type

Sponsor Type for CATAPRES-TTS-3
Sponsor	Trials
Other	36
NIH	5
Industry	4

CATAPRES-TTS-3 Market Analysis and Financial Projection

Last updated: April 28, 2026

Catapres-TTS-3 (clonidine hydrochloride transdermal system): clinical trials update, market analysis, and projection

What is Catapres-TTS-3 and what does it cover?

Catapres-TTS-3 is a clonidine hydrochloride transdermal delivery system marketed in the US as a patch. It delivers clonidine for systemic treatment of hypertension. In practice, “Catapres-TTS-3” is the 3 mg strength patch within the Catapres-TTS line (other strengths exist, but this analysis is scoped to the 3 mg product name used in market and reference materials).

Product scope used for this report

• Drug/active: Clonidine hydrochloride
• Dosage form: Transdermal system (patch)
• Strength referenced: 3 mg (Catapres-TTS-3 naming convention)
• Indication (core US label): Hypertension
• Brand: Catapres-TTS
• Route: Transdermal

What clinical trials updates matter for Catapres-TTS-3?

No new, sponsor-level, late-stage clinical development updates tied specifically to the branded “Catapres-TTS-3” product name are reliably trackable in public registries as discrete “modern trial programs” beyond historical clonidine transdermal development. The clinical evidence base for clonidine transdermal therapy is mature and product lifecycle activity is dominated by:

• label maintenance,
• comparative effectiveness in broader clonidine or patch therapy contexts,
• pharmacovigilance and real-world safety monitoring,
• formulation or manufacturing changes that do not typically register as brand-specific late-stage trials.

Implication for business and investment

• The brand behaves like a mature, platform product: incremental evidence generation is more likely to be post-marketing, comparative, or regimen-based rather than a discrete late-stage brand trial that would move valuation in the way a Phase 3 pivotal readout does.

How is Catapres-TTS-3 positioned in the market?

Catapres-TTS-3 sits in an older antihypertensive class ecosystem. Clonidine is an alpha-2 adrenergic agonist with established use patterns, but the US and EU hypertension markets have structurally shifted toward:

• first-line classes (ACE inhibitors, ARBs, calcium channel blockers, thiazide-like diuretics),
• fixed-dose combinations,
• guideline-aligned escalation pathways that usually reserve clonidine for later-line or specific clinical scenarios.

Where clonidine patches still make sense commercially

• Patients who need a transdermal route (adherence issues or oral intolerance)
• Specific clinical settings where clinicians use clonidine-based regimens (protocol-driven use)
• Transition-of-care scenarios where clinicians prefer patch continuity over tablet switching

Competitive landscape

• Direct brand-to-brand competition: Other clonidine transdermal options and generic clonidine patch equivalents, where available, compete on net pricing and formulary access.
• Therapeutic competition: Newer and guideline-favored antihypertensive categories reduce addressable volume for clonidine.

Commercial reality Catapres-TTS-3 economics typically hinge less on differentiation and more on:

• formulary status (managed care),
• discounting and rebate structure,
• substitution and generic penetration (where applicable),
• availability and manufacturing consistency.

What is the unit economics logic for this product in 2026?

For mature antihypertensive patches, business models usually track two drivers:

1. Volume resilience from adherence and regimen lock-in.
2. Price erosion under generic pressure and payer preference for guideline-first agents.

Catapres-TTS-3’s value proposition is route-based (patch), not novel pharmacology. That tends to cap premium pricing and increases the influence of payer step therapy and substitution.

Market analysis: demand drivers and constraints

Key demand drivers

• Ongoing hypertension prevalence and long-duration treatment need
• Route preference where patch adherence improves outcomes in practice
• Clinician and care team familiarity with clonidine transdermal dosing

Key constraints

• Strong guideline preference for first-line antihypertensives
• Class-side-effect and tolerability considerations that limit broad use
• Generic substitution dynamics (when lower-cost alternatives are accessible)
• Payer formulary tightening and preference for combination regimens

Market projection framework (2026–2031)

Because Catapres-TTS-3 is a mature, off-patent-type branded product profile in most markets, the projection logic is typically dominated by:

• macro hypertension treatment stability,
• share shifts caused by formulary and guideline adherence,
• pricing decline due to competition,
• limited upside from new clinical indications (none identified as brand-specific late-stage value inflection in current public registries).

Projection outcomes used in this report

• Base case: low-single-digit annual revenue decline in nominal terms due to price erosion offset partly by volume stability.
• Downside case: mid-single-digit annual nominal decline if payer restrictions intensify or substitution accelerates.
• Upside case: flat to low-positive growth if access improves and adherence-based retention stays resilient.

Catapres-TTS-3 revenue trend (directional)

• 2026–2028: mild negative trajectory (pricing pressure dominates; volume stable)
• 2029–2031: continuing erosion with slower decline rates if volume retention holds

Note: A numeric market forecast with exact $ values requires brand-level sales baselines and segmentation by region, payer, and strength. Those data are not present in the provided context, and the report cannot generate an accurate figure without them.

Where would the biggest risk to projection come from?

• Formulary changes that reduce patch usage in hypertension pathways
• Broader substitution by generics or alternative delivery forms
• Any safety signal that changes prescribing behavior at the class level
• Shifts in guideline emphasis that reduce clonidine patch role in routine hypertension management

What would create upside?

• Expansion into a distinct care pathway where transdermal clonidine has protocol-based use (not a new indication trial readout, but real-world treatment patterns)
• Improvement in payer coverage for patch products specifically
• Retention gains driven by adherence and fewer switching events

---

Key Takeaways

• Catapres-TTS-3 is a mature clonidine transdermal hypertension product; its business outlook is dominated by payer access, generic substitution dynamics, and pricing pressure rather than brand-specific late-stage clinical development.
• Public clinical trial activity tied specifically to “Catapres-TTS-3” as a distinct modern program is not evidenced as a discrete, pipeline-moving Phase 3 effort; most ongoing activity is post-marketing and broader clonidine patch research.
• Market projection is directionally negative to flat across 2026–2031 in nominal terms in typical mature antihypertensive patch scenarios, with the main swing factor being formulary and substitution intensity.

---

FAQs

1) Is Catapres-TTS-3 a “new” clinical development product?

No. Catapres-TTS-3 is a mature branded clonidine patch product; current value drivers are access and pricing more than new pivotal clinical readouts.

2) What drives demand for clonidine patches in hypertension?

Clinical and payer behavior that supports transdermal therapy, plus patient adherence needs that keep patch regimens stable.

3) What typically limits growth for mature antihypertensive patches?

Guideline-first prescribing toward other drug classes and pricing erosion under competition and substitution.

4) How do clinical trials affect Catapres-TTS-3 valuation now?

They matter mainly for post-marketing evidence, comparative positioning, and safety surveillance rather than near-term, brand-shaping pivotal outcomes.

5) What is the biggest determinant of near-term revenue trajectory?

Formulary coverage and replacement/substitution patterns at the patch strength and package level.

---

References

[1] FDA. Catapres-TTS (clonidine transdermal system) prescribing information. U.S. Food and Drug Administration.
[2] ClinicalTrials.gov. Search results for clonidine transdermal system / Catapres-TTS (public registry records). National Library of Medicine.
[3] ACC/AHA. 2017 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. American College of Cardiology/American Heart Association.